Exhibit
31.1



CERTIFICATION

PURSUANT TO18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 302 OF

THE
SARBANES-OXLEY ACT OF 2002 PURSUANT TOREGULATION

SS.240.15D-14 AS PROMULGATED BY

THE
SECURITIES AND EXCHANGE COMMISSION

CEO AND CFO CERTIFICATION



I,
Miro Zecevic, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
pursuant to Regulation ss.240.15d-14 as promulgated by the Securities and Exchange Commission, that:



1.  	I
have reviewed this report on Form 10-Q of 024 Pharma, Inc.



2.  	Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;



3.  	Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented
in this report;



4.  	I
am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the
registrant and have:



a)  	Designed
such disclosure controls and procedures, or caused such control and procedures to be designed under our supervision, to ensure
that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being prepared;



b)  	Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;



c)  	Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation, and



d)  	Disclosed
in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s
internal control over financial reporting; and



5.  	I
have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors
and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



| | (a) | All
                                         significant deficiencies and material weaknesses in the design or operation of internal
                                         control over financial reporting which are reasonably likely to adversely affect the
                                         registrant's ability to record, process, summarize and report financial information;
                                         and
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | (b) | Any
                                         fraud, whether or not material, that involves management or other employees who have
                                         a significant role in the registrant's internal control over financial reporting.
| | --- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------







|Date:
April 11, 2017 | By: | /s/Miro Zecevic             | 
|-------------------- | --- | --------------------------- | 
|                     |     | Miro Zecevic                | 
|                     |     | Chief Executive Officer and | 
|                     |     | Chief
    Financial Officer |